000 02726na a2200397 4500
999 _c14001
_d14001
003 PC14001
005 20210625062813.0
008 130622s2013 xxx||||| |||| 00| 0 eng d
040 _cH12O
041 _aeng
100 _aGómez de la Cámara, Agustín
_91011
_eEpidemiología Clínica
245 0 0 _aSocio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients.
_h[artículo]
260 _c2013
_bNordic Journal of Psychiatry,
300 _a67(1):22-9.
500 _aFormato Vancouver: San L, Bernardo M, Gómez A, Martínez P, González B, Peña M. Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients. Nord J Psychiatry. 2013 Feb;67(1):22-9. doi: 10.3109/08039488.2012.667150.
501 _aPMID: 22429047
504 _aContiene 34 referencias.
520 _aAims: To define the clinical profile of relapsing patients with schizophrenia attended in daily practice. Method: Patients with schizophrenia/schizoaffective disorder admitted to short-stay/acute-care psychiatric units were eligible provided that data for the previous 3 years and for the next 12 months after discharge were collected. Results: Remarking features in 1646 patients (68% men) included low family support (34%), primary education (48%), schizophrenia as the main diagnosis (77%), duration of illness > 10 years (60%), mean number of previous hospitalizations of 2.74, non-adherence as the main reason of hospitalization (58.6%), treatment with a mean of two different antipsychotics and differences in adherence according to antipsychotic medication (P < 0.0001) (highest rates for depot atypical antipsychotics). The relapse rate was 38.6%. There were no differences in the number of relapsing patients according to antipsychotic drugs. Discussion and conclusion: The profile of relapsing schizophrenic patients may be defined as a male subject, aged 30-45 years, with primary education level, more than 10 years of disease' duration, low family support, moderately and severely ill, treated with multiple antipsychotic drugs, and poor to moderate adherence. Differences in relapse according to antipsychotic types were not observed but long-acting second generation antipsychotic drugs showed the highest percentage of maximum adherence.
710 _9625
_aInstituto de Investigación imas12
856 _uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc14001.pdf
_ySolicitar documento
942 _n0
_2ddc
_cART